• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

ABCB1 c.2677G>T 变异与 ADHD 儿童和青少年 OROS-哌甲酯不良反应相关。

ABCB1 c.2677G>T variation is associated with adverse reactions of OROS-methylphenidate in children and adolescents with ADHD.

机构信息

Department of Pharmacology, Pharmacogenomic Research Center for Membrane Transporters, Brain Korea 21 Project for Medical Science, Seoul, Korea.

出版信息

J Clin Psychopharmacol. 2013 Aug;33(4):491-8. doi: 10.1097/JCP.0b013e3182905a8d.

DOI:10.1097/JCP.0b013e3182905a8d
PMID:23771192
Abstract

OBJECTIVES

Osmotic-release oral system (OROS)-methylphenidate (MPH) is a safe and well-tolerated drug. Some patients cannot continue this regimen with adverse drug reactions (ADRs). As drug efflux transporters of the central nervous system, ABCB1 plays an important role in the clearance of psychotropic drugs and their metabolites from brain tissues. We hypothesized that genetic variations in the ABCB1 gene may affect ADRs to OROS-MPH.

METHODS

We analyzed ADRs of OROS-MPH in 134 children and adolescents with attention-deficit hyperactivity disorder who completed a 4-week trial of OROS-MPH. The ADRs of OROS-MPH were evaluated by administering the Barkley Stimulant Side Effects Rating Scale.

RESULTS

Our study proved that MPH is a substrate for ABCB1 by using membrane vesicle assay. We analyzed the influence of ABCB1 polymorphisms on ADRs to OROS-MPH. From the association study between ABCB1 polymorphisms and ADRs of OROS-MPH, c.2677G>T (p.Ala893Ser, rs2032582) showed a strong association with OROS-MPH-related ADRs (P = 0.008; odds ratio, 5.72). Furthermore, logistic regression analysis indicated that the TT genotype at the ABCB1 2677 locus is an independent determinant of ADRs attributed to OROS-MPH. In a functional study, the 893Ser variant markedly reduced MPH transport across the cell membrane.

CONCLUSIONS

This is the first study to demonstrate that the TT genotype at position 2677 in the ABCB1 gene is associated with ADRs to OROS-MPH.

摘要

目的

渗透释放口腔系统(OROS)-哌甲酯(MPH)是一种安全且耐受良好的药物。一些患者由于不良反应(ADR)而无法继续使用该方案。作为中枢神经系统的药物外排转运蛋白,ABCB1 在精神药物及其代谢物从脑组织中的清除中起着重要作用。我们假设 ABCB1 基因的遗传变异可能会影响 OROS-MPH 的 ADR。

方法

我们分析了 134 名患有注意缺陷多动障碍的儿童和青少年在接受 OROS-MPH 为期 4 周的试验期间的 OROS-MPH 的 ADR。通过 Barkley 兴奋剂副作用评定量表评估 OROS-MPH 的 ADR。

结果

我们的研究通过膜囊泡测定证明了 MPH 是 ABCB1 的底物。我们分析了 ABCB1 多态性对 OROS-MPH 的 ADR 的影响。从 ABCB1 多态性与 OROS-MPH 的 ADR 之间的关联研究中,c.2677G>T(p.Ala893Ser,rs2032582)与 OROS-MPH 相关的 ADR 具有很强的相关性(P=0.008;优势比,5.72)。此外,逻辑回归分析表明,ABCB1 2677 位点的 TT 基因型是 OROS-MPH 相关 ADR 的独立决定因素。在功能研究中,893Ser 变体明显降低了 MPH 通过细胞膜的转运。

结论

这是第一项表明 ABCB1 基因 2677 位的 TT 基因型与 OROS-MPH 的 ADR 相关的研究。

相似文献

1
ABCB1 c.2677G>T variation is associated with adverse reactions of OROS-methylphenidate in children and adolescents with ADHD.ABCB1 c.2677G>T 变异与 ADHD 儿童和青少年 OROS-哌甲酯不良反应相关。
J Clin Psychopharmacol. 2013 Aug;33(4):491-8. doi: 10.1097/JCP.0b013e3182905a8d.
2
Norepinephrine transporter -3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment.去甲肾上腺素转运蛋白-3081(A/T) 和α-2A-肾上腺素能受体 MspI 多态性与 OROS-哌甲酯治疗的心血管副作用有关。
J Psychopharmacol. 2012 Mar;26(3):380-9. doi: 10.1177/0269881111405356. Epub 2011 May 31.
3
Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.在 ADHD 儿童/青少年中,从缓释哌甲酯转换为渗透控释哌甲酯的效果:一项 3 个月非干预性研究的结果。
Curr Med Res Opin. 2011;27 Suppl 2:35-44. doi: 10.1185/03007995.2011.601733. Epub 2011 Jul 25.
4
Val/Val genotype of brain-derived neurotrophic factor (BDNF) Val⁶⁶Met polymorphism is associated with a better response to OROS-MPH in Korean ADHD children.脑源性神经营养因子(BDNF)Val⁶⁶Met 多态性的 Val/Val 基因型与韩国 ADHD 儿童对 OROS-MPH 的更好反应相关。
Int J Neuropsychopharmacol. 2011 Nov;14(10):1399-410. doi: 10.1017/S146114571100099X. Epub 2011 Jun 28.
5
Developing a Risk Score to Guide Individualized Treatment Selection in Attention Deficit/Hyperactivity Disorder.开发一种风险评分以指导注意缺陷多动障碍的个体化治疗选择
Value Health. 2015 Sep;18(6):824-31. doi: 10.1016/j.jval.2015.06.005. Epub 2015 Aug 20.
6
Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.渗透泵控释口服系统哌甲酯与托莫西汀治疗中国青少年注意力缺陷/多动障碍:8周疗效对比及1年随访
J Child Adolesc Psychopharmacol. 2016 May;26(4):362-71. doi: 10.1089/cap.2015.0031. Epub 2016 Jan 18.
7
Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.在三种注意缺陷多动障碍(ADHD)亚型中,对于速释型哌甲酯依从性差的患者,渗透型口服系统哌甲酯疗效更佳。
Psychiatry Clin Neurosci. 2009 Apr;63(2):167-75. doi: 10.1111/j.1440-1819.2009.01937.x.
8
Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH.探索每日一次 OROS®哌甲酯(MPH)对从速释 MPH 转换的 ADHD 儿童和青少年的症状和生活质量的影响。
Postgrad Med. 2011 Sep;123(5):27-38. doi: 10.3810/pgm.2011.09.2457.
9
Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder.托莫西汀和渗透泵控释型哌甲酯对注意缺陷多动障碍(混合型)患者执行功能的影响
J Child Adolesc Psychopharmacol. 2015 Aug;25(6):494-500. doi: 10.1089/cap.2014.0155. Epub 2015 Jul 28.
10
OROS-methylphenidate efficacy on specific executive functioning deficits in adults with ADHD: a randomized, placebo-controlled cross-over study.奥罗莫苯丙胺对 ADHD 成人特定执行功能缺陷的疗效:一项随机、安慰剂对照交叉研究。
Eur Neuropsychopharmacol. 2014 Apr;24(4):519-28. doi: 10.1016/j.euroneuro.2014.01.007. Epub 2014 Jan 18.

引用本文的文献

1
An Updated Review of Genetic Associations With Severe Adverse Drug Reactions: Translation and Implementation of Pharmacogenomic Testing in Clinical Practice.严重药物不良反应的遗传关联最新综述:临床实践中药基因组检测的转化与应用
Front Pharmacol. 2022 Apr 25;13:886377. doi: 10.3389/fphar.2022.886377. eCollection 2022.
2
Pharmacokinetics of Tenofovir Alafenamide Fumarate and Tenofovir in the Chinese People: Effects of Non-Genetic Factors and Genetic Variations.富马酸替诺福韦艾拉酚胺和替诺福韦在中国人群中的药代动力学:非遗传因素和基因变异的影响
Pharmgenomics Pers Med. 2021 Oct 14;14:1315-1329. doi: 10.2147/PGPM.S329690. eCollection 2021.
3
Outcomes of a 12-week ecologically valid observational study of first treatment with methylphenidate in a representative clinical sample of drug naïve children with ADHD.
一项为期 12 周的、针对首次接受哌醋甲酯治疗的 ADHD 药物初治儿童的具有生态学效度的观察性研究结果。
PLoS One. 2021 Oct 21;16(10):e0253727. doi: 10.1371/journal.pone.0253727. eCollection 2021.
4
Evaluation of Methylphenidate Safety and Maximum-Dose Titration Rationale in Attention-Deficit/Hyperactivity Disorder: A Meta-analysis.评估哌醋甲酯在注意缺陷多动障碍中的安全性和最大剂量滴定原理:一项荟萃分析。
JAMA Pediatr. 2019 Jul 1;173(7):630-639. doi: 10.1001/jamapediatrics.2019.0905.
5
PharmGKB summary: methylphenidate pathway, pharmacokinetics/pharmacodynamics.药物基因组学知识库总结:哌甲酯途径,药代动力学/药效学。
Pharmacogenet Genomics. 2019 Aug;29(6):136-154. doi: 10.1097/FPC.0000000000000376.
6
Increasing BMI is associated with reduced expression of P-glycoprotein (ABCB1 gene) in the human brain with a stronger association in African Americans than Caucasians.体重指数(BMI)的增加与人类大脑中P-糖蛋白(ABCB1基因)表达降低有关,且非裔美国人的这种关联比白种人更强。
Pharmacogenomics J. 2018 Jan;18(1):121-126. doi: 10.1038/tpj.2016.74. Epub 2016 Nov 29.